|
Health Economics
Citations 1-10 of 94 total displayed.
|
Most recent content
(1 Jan 2008):
|
- CLINICAL
The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit
- R. M. Ara, J. C. Packham, and K. L. Haywood
Rheumatology 2008; 47: 68-71.
[Abstract]
[Full Text]
|
Past content
(since Jan 2001):
|
- CLINICAL
An economic evaluation of three physiotherapy treatments for non-specific neck disorders alongside a randomized trial
- M. Lewis, M. James, E. Stokes, J. Hill, J. Sim, E. Hay, and K. Dziedzic
Rheumatology 2007; 46: 1701-1708.
[Abstract]
[Full Text]
- EDITORIALS
30 million, around 10 000 ... and 18 ... Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service
- D. A. Isenberg
Rheumatology 2007; 46: 1219-1220.
[Extract]
[Full Text]
- BASIC SCIENCE
Interleukin (IL)-23 p19 expression induced by IL-1ß in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor- B and AP-1 dependent pathway
- F.-L. Liu, C.-H. Chen, S.-J. Chu, J.-H. Chen, J.-H. Lai, H.-K. Sytwu, and D.-M. Chang
Rheumatology 2007; 46: 1266-1273.
[Abstract]
[Full Text]
- CLINICAL
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
- M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout
Rheumatology 2007; 46: 1320-1328.
[Abstract]
[Full Text]
- CLINICAL
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
- A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons
Rheumatology 2007; 46: 1345-1354.
[Abstract]
[Full Text]
- MATTERS ARISING
Rheumatology nurse specialists—do we need them?
- S. M. Oliver
Rheumatology 2007; 46: 1380-1381.
[Extract]
[Full Text]
- CLINICAL
The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis
- E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham
Rheumatology 2007; 46: 1096-1101.
[Abstract]
[Full Text]
- CLINICAL
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
- C. A. E. Walsh, P. Minnock, C. Slattery, N. Kennedy, F. Pang, D. J. Veale, B. Bresnihan, and O. FitzGerald
Rheumatology 2007; 46: 1148-1152.
[Abstract]
[Full Text]
- GUIDELINES
Provisional guidelines for applying the Department of Health (England) 18-week-patient pathway to specialist rheumatology care
- D. A. Walsh, C. Kelly, A. Bosworth, C. Price, and G. Burbage
Rheumatology 2007; 46: 1200-1206.
[Abstract]
[Full Text]
|
|